Skip to content
AnalystLens

Insmed 8-K Report, Financial Results (Aug 8, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed August 8, 2024
Period End
August 8, 2024
Security
INSM
In the record · 2016–202610-K1110-Q338-K134

INSM filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’18Jan ’18
  2. Leadership change8-K · May ’20May ’20
  3. Material agreement8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed August 8, 2024. Cited figures are marked; the original filing is the authoritative source.

Insmed Incorporated reported financial results for the second quarter ended June 30, 2024, in a press release furnished as Exhibit 99.1 to this Item 2.02 Form 8-K.

Total revenue was $90.3 milliona, up 17% from $77.2 million in the second quarter of 2023, driven by ARIKAYCE net sales of $63.8 million in the U.S., $21.1 million in Japan, and $5.4 million in Europe and rest of world. The company reported a net loss of $300.6 million, or $1.94 per share, compared with a net loss of $244.8 million, or $1.78 per share, a year earlier. The loss was affected by a non-cash expense of $103.7 million from the change in fair value of deferred and contingent consideration liabilities, which the company attributed primarily to the increase in its share price during the quarter.

The company reiterated its 2024 global ARIKAYCE revenue guidance of $340 million to $360 millionb. It said it plans to file a New Drug Application for brensocatib in bronchiectasis in the fourth quarter of 2024, with a U.S. launch anticipated in mid-2025 pending approvals. As of June 30, 2024, cash and cash equivalents totaled $1.25 billion, and shareholders' equity was $38.8 million.

During the quarter the company completed a public offering with net proceeds of $713.2 millionc, and it redeemed its 1.75% convertible senior notes due January 2025, with 99.9% of the notes converted into common stock before the August 9, 2024 redemption date. The filing also outlines pipeline milestones, including positive topline data from the Phase 3 ASPEN study of brensocatib in May 2024, agreement with the FDA on the primary endpoint for the Phase 3 ENCORE study of ARIKAYCE, and a plan to report ENCORE topline data in the first quarter of 2026. The press release also includes ARIKAYCE's boxed warning for respiratory adverse reactions and its safety information.

02—Key points

Key Highlights

  1. Total revenue of $90.3 million for Q2 2024, up 17% from $77.2 million in Q2 2023, with U.S. ARIKAYCE sales of $63.8 million (up 11% year over year).
  2. Net loss widened to $300.6 million ($1.94 per share) from $244.8 million ($1.78 per share) in Q2 2023, including a $103.7 million non-cash charge tied to contingent consideration liabilities.
  3. R&D expenses fell to $146.7 million from $197.0 million, mainly due to the prior-year non-cash cost of the Adrestia acquisition; SG&A rose to $106.6 million from $84.4 million.
  4. Reiterated 2024 global ARIKAYCE revenue guidance of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared with 2023.
  5. NDA submission for brensocatib in bronchiectasis planned for Q4 2024, with a U.S. launch anticipated in mid-2025 pending approval; Phase 3 ASPEN topline data were positive in May 2024.
  6. Cash and cash equivalents of $1,246.8 million at June 30, 2024, after a public offering with net proceeds of $713.2 million; total shareholders' equity was $38.8 million.
  7. Redemption of the $225 million 1.75% convertible senior notes due January 2025, with 99.9% converted into approximately 5.7 million shares before the August 9, 2024 redemption date.

03—Questions

Frequently Asked Questions

  1. How did Insmed's revenue perform in the second quarter of 2024?

    Total revenue was $90.3 million, reflecting 17% growth from $77.2 million in the second quarter of 2023. ARIKAYCE net sales were $63.8 million in the U.S., $21.1 million in Japan, and $5.4 million in Europe and rest of world, with year-over-year growth of 11%, 35%, and 37%, respectively.

  2. Why was the net loss larger than in the prior-year quarter?

    The net loss was $300.6 million, or $1.94 per share, compared with $244.8 million, or $1.78 per share, in Q2 2023. The filing cites a non-cash expense of $103.7 million from the change in fair value of deferred and contingent consideration liabilities, which primarily resulted from the increase in the company's share price during the quarter.

  3. What regulatory and commercial milestones are expected next for brensocatib?

    Insmed plans to file a New Drug Application with the FDA for brensocatib in bronchiectasis in the fourth quarter of 2024. Pending regulatory approvals, it anticipates a U.S. launch in mid-2025 and launches in Europe and Japan in the first half of 2026.

  4. What guidance did Insmed provide for 2024?

    The company reiterated full-year 2024 global ARIKAYCE revenue guidance of $340 million to $360 million, which it said represents 15% year-over-year growth at the midpoint compared with 2023.

  5. How did the company strengthen its balance sheet during the quarter?

    Insmed completed a public offering of 14,514,562 shares of common stock, including the full exercise of the underwriters' option, with net proceeds of $713.2 million. It also redeemed its 1.75% convertible senior notes, with 99.9% converted into about 5.7 million shares before the August 9, 2024 redemption date. Cash and cash equivalents were $1,246.8 million at June 30, 2024.

04—Continue

← View all 8-K filings